214 related articles for article (PubMed ID: 23735014)
1. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates.
Todd TE; Tibi O; Lin Y; Sayers S; Bronner DN; Xiang Z; He Y
BMC Bioinformatics; 2013; 14 Suppl 6(Suppl 6):S3. PubMed ID: 23735014
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of vaccination strategies against intranasal challenge with Brucella abortus in BALB/c mice.
Surendran N; Sriranganathan N; Lawler H; Boyle SM; Hiltbold EM; Heid B; Zimmerman K; Witonsky SG
Vaccine; 2011 Mar; 29(15):2749-55. PubMed ID: 21316499
[TBL] [Abstract][Full Text] [Related]
3. Booster vaccination with safe, modified, live-attenuated mutants of Brucella abortus strain RB51 vaccine confers protective immunity against virulent strains of B. abortus and Brucella canis in BALB/c mice.
Truong QL; Cho Y; Kim K; Park BK; Hahn TW
Microbiology (Reading); 2015 Nov; 161(11):2137-48. PubMed ID: 26341622
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Efficacy of the Brucella canis RM6/66 Δ
Stranahan LW; Chaki SP; Garcia-Gonzalez DG; Khalaf OH; Arenas-Gamboa AM
mSphere; 2020 May; 5(3):. PubMed ID: 32434839
[No Abstract] [Full Text] [Related]
5. Meta-Analysis and Advancement of Brucellosis Vaccinology.
Carvalho TF; Haddad JP; Paixão TA; Santos RL
PLoS One; 2016; 11(11):e0166582. PubMed ID: 27846274
[TBL] [Abstract][Full Text] [Related]
6. Protective live oral brucellosis vaccines stimulate Th1 and th17 cell responses.
Clapp B; Skyberg JA; Yang X; Thornburg T; Walters N; Pascual DW
Infect Immun; 2011 Oct; 79(10):4165-74. PubMed ID: 21768283
[TBL] [Abstract][Full Text] [Related]
7. Protective efficacy and safety of Brucella melitensis 16MΔmucR against intraperitoneal and aerosol challenge in BALB/c mice.
Arenas-Gamboa AM; Rice-Ficht AC; Kahl-McDonagh MM; Ficht TA
Infect Immun; 2011 Sep; 79(9):3653-8. PubMed ID: 21708998
[TBL] [Abstract][Full Text] [Related]
8. Aerosol infection of BALB/c mice with Brucella melitensis and Brucella abortus and protective efficacy against aerosol challenge.
Kahl-McDonagh MM; Arenas-Gamboa AM; Ficht TA
Infect Immun; 2007 Oct; 75(10):4923-32. PubMed ID: 17664263
[TBL] [Abstract][Full Text] [Related]
9. Over-expression of homologous antigens in a leucine auxotroph of Brucella abortus strain RB51 protects mice against a virulent B. suis challenge.
Rajasekaran P; Surendran N; Seleem MN; Sriranganathan N; Schurig GG; Boyle SM
Vaccine; 2011 Apr; 29(17):3106-10. PubMed ID: 21376799
[TBL] [Abstract][Full Text] [Related]
10. Targeting resident memory T cell immunity culminates in pulmonary and systemic protection against Brucella infection.
Wang H; Hoffman C; Yang X; Clapp B; Pascual DW
PLoS Pathog; 2020 Jan; 16(1):e1008176. PubMed ID: 31951645
[TBL] [Abstract][Full Text] [Related]
11. Research progress in live attenuated Brucella vaccine development.
Wang Z; Wu Q
Curr Pharm Biotechnol; 2013; 14(10):887-96. PubMed ID: 24372253
[TBL] [Abstract][Full Text] [Related]
12. The candidate vaccine strain Brucella ovis ∆abcBA is protective against Brucella melitensis infection in mice.
Costa LF; Cabello AL; Batista DFA; Chaki SP; de Figueiredo P; da Paixão TA; Rice-Ficht AC; Ficht TA; Santos RL
Microbiol Immunol; 2020 Nov; 64(11):730-736. PubMed ID: 32965738
[TBL] [Abstract][Full Text] [Related]
13. Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4.
Winter AJ; Schurig GG; Boyle SM; Sriranganathan N; Bevins JS; Enright FM; Elzer PH; Kopec JD
Am J Vet Res; 1996 May; 57(5):677-83. PubMed ID: 8723881
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of protection afforded by Brucella abortus and Brucella melitensis unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice.
Kahl-McDonagh MM; Ficht TA
Infect Immun; 2006 Jul; 74(7):4048-57. PubMed ID: 16790778
[TBL] [Abstract][Full Text] [Related]
15. Attenuated Salmonella secreting Brucella protective antigens confer dual-faceted protection against brucellosis and salmonellosis in a mouse model.
Senevirathne A; Hewawaduge C; Lee JH
Vet Immunol Immunopathol; 2019 Mar; 209():31-36. PubMed ID: 30885303
[TBL] [Abstract][Full Text] [Related]
16. Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice.
Vemulapalli R; Contreras A; Sanakkayala N; Sriranganathan N; Boyle SM; Schurig GG
Vet Microbiol; 2004 Sep; 102(3-4):237-45. PubMed ID: 15327798
[TBL] [Abstract][Full Text] [Related]
17. Extended safety and efficacy studies of the attenuated Brucella vaccine candidates 16 M(Delta)vjbR and S19(Delta)vjbR in the immunocompromised IRF-1-/- mouse model.
Arenas-Gamboa AM; Rice-Ficht AC; Fan Y; Kahl-McDonagh MM; Ficht TA
Clin Vaccine Immunol; 2012 Feb; 19(2):249-60. PubMed ID: 22169089
[TBL] [Abstract][Full Text] [Related]
18. Brucella suis strain 2 vaccine is safe and protective against heterologous Brucella spp. infections.
Zhu L; Feng Y; Zhang G; Jiang H; Zhang Z; Wang N; Ding J; Suo X
Vaccine; 2016 Jan; 34(3):395-400. PubMed ID: 26626213
[TBL] [Abstract][Full Text] [Related]
19. A Brucella melitensis M5-90 wboA deletion strain is attenuated and enhances vaccine efficacy.
Li ZQ; Shi JX; Fu WD; Zhang Y; Zhang J; Wang Z; Li TS; Chen CF; Guo F; Zhang H
Mol Immunol; 2015 Aug; 66(2):276-83. PubMed ID: 25899866
[TBL] [Abstract][Full Text] [Related]
20. The Brucella melitensis M5-90ΔmanB live vaccine candidate is safer than M5-90 and confers protection against wild-type challenge in BALB/c mice.
Zhang J; Yin S; Yi D; Zhang H; Li Z; Guo F; Chen C; Fang W; Wang J
Microb Pathog; 2017 Nov; 112():148-155. PubMed ID: 28916316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
